Hikal Limited
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are…
What Hikal files
- Others53
- Important34
- Investor Meet28
- Updates16
- Board Meeting12
- Dividend/Bonus8
Hikal has announced its 38th Annual General Meeting. The Annual Report for FY26 is available on the company website. Shareholders must update KYC details and dematerialize physical shares to ensure receipt of future payments like dividends.
Hikal's full-year results show a loss of 48.7 Cr on revenue of 1,712.6 Cr due to headwinds and exceptional charges. Operational recovery is underway, boosting optimism. The company commissioned new HPAPI and Kilo labs, launched a Personal Care facility, and proposed Sameer Hiremath as Chairman & MD.
Hikal Ltd. has announced its 38th Annual General Meeting where members will vote on the proposed final dividend. A record date is set to determine eligible shareholders for this dividend payment, which will be paid post-declaration.
Hikal's Q1FY27 revenue hit ₹403 Cr (+6.2% YoY), EBITDA ₹37 Cr (+47.4%). Pharma saw recovery (+15.2%) with new cGMP plant. Crop Protection's CDMO was soft, but Own Products grew. Personal Care business commercialized. US FDA remediation is ongoing.
Hikal secured an EcoVadis Gold Medal for sustainability, ranking in the top 5% globally. This strengthens credibility with global customers and investors, signaling strong ESG performance and commitment to responsible growth and long-term value creation.